Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Nature Medicine
Volume 27 Issue 11, November 2021
https://www.nature.com/nm/volumes/27/issues/11

 

Article | 30 September 2021
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
After two doses of the BNT162b2 vaccine, virus-specific antibodies and T cells were reduced in patients with solid tumors as compared to individuals without cancer, but neutralizing antibodies increased in most patients who received a third vaccine dose.
Rachna T. Shroff, Pavani Chalasani, Deepta Bhattacharya